The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.
CYP3A4 protein results in decreased methylation of Diltiazem Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Diltiazem inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; potassium ferricyanide inhibits the reaction [Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; potassium ferricyanide inhibits the reaction [Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; potassium ferricyanide inhibits the reaction [Diltiazem results in decreased activity of CYP3A4 protein]; potassium ferricyanide promotes the reaction [Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; potassium ferricyanide promotes the reaction [Diltiazem inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]] CYP3A4 protein affects the metabolism of Diltiazem
CYP3A5 protein affects the metabolism of Diltiazem; CYP3A5 protein polymorphism affects the metabolism of Diltiazem CYP3A5 protein results in decreased methylation of Diltiazem
Diltiazem inhibits the reaction [[NFKB1 protein binds to RELA protein] which binds to IL12A promoter]; Diltiazem inhibits the reaction [Lipopolysaccharides results in increased expression of [IL12A protein binds to IL12B protein]]; Diltiazem inhibits the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA] Diltiazem results in decreased expression of IL12A mRNA
Diltiazem inhibits the reaction [[NFKB1 protein binds to RELA protein] which binds to IL12B promoter]; Diltiazem inhibits the reaction [Lipopolysaccharides results in increased expression of [IL12A protein binds to IL12B protein]]; Diltiazem inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA] Diltiazem results in decreased expression of IL12B mRNA
Diltiazem affects the localization of NFKB1 protein [Diltiazem co-treated with Lipopolysaccharides] affects the localization of NFKB1 protein; Diltiazem inhibits the reaction [[NFKB1 protein binds to RELA protein] which binds to IL12A promoter]; Diltiazem inhibits the reaction [[NFKB1 protein binds to RELA protein] which binds to IL12B promoter]; Diltiazem results in decreased activity of [NFKB1 protein binds to RELA protein]
Diltiazem inhibits the reaction [[NFKB1 protein binds to RELA protein] which binds to IL12A promoter]; Diltiazem inhibits the reaction [[NFKB1 protein binds to RELA protein] which binds to IL12B promoter]; Diltiazem results in decreased activity of [NFKB1 protein binds to RELA protein]